Zacks Investment Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research report sent to investors on Friday.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

A number of other brokerages have also recently weighed in on COLL. Piper Jaffray Companies set a $33.00 price target on shares of Collegium Pharmaceutical and gave the company a buy rating in a research report on Tuesday, January 23rd. Jefferies Group lifted their price target on shares of Collegium Pharmaceutical to $27.00 and gave the company a buy rating in a research report on Tuesday, December 5th. Needham & Company LLC lifted their price target on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a buy rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright reiterated a buy rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. Finally, BidaskClub cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical has a consensus rating of Buy and an average target price of $25.00.

Collegium Pharmaceutical (NASDAQ COLL) opened at $22.60 on Friday. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $26.77. The company has a market cap of $735.91 and a PE ratio of -7.61.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. During the same period last year, the business earned ($1.13) earnings per share. The business’s revenue for the quarter was up 2814.6% on a year-over-year basis. analysts predict that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.

In other news, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $17.34, for a total transaction of $17,340,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Insiders sold 1,105,558 shares of company stock valued at $19,346,677 in the last 90 days. Company insiders own 25.76% of the company’s stock.

Large investors have recently modified their holdings of the company. Pura Vida Investments LLC purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth approximately $1,229,000. Teton Advisors Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth approximately $283,000. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after buying an additional 39,656 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 98.8% during the 2nd quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock worth $745,000 after buying an additional 29,617 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Collegium Pharmaceutical by 18.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock worth $13,951,000 after buying an additional 211,288 shares during the last quarter. Institutional investors and hedge funds own 82.29% of the company’s stock.

WARNING: “Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-coll-downgraded-by-zacks-investment-research/1845120.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.